Neopharm’s Anti-Bribery & Anti-Corruption Policy
Neopharm recognizes the detrimental impact bribery and corruption has on society.
Neopharm is committed to conducting its business throughout the world with integrity, the highest ethical standards, and in compliance with applicable anti-bribery/anti-corruption (“ABAC”) laws, rules, regulations, codes and guidelines.
Our policy sets out how we operate transparently and with vigilance to prevent and support the detection and investigation of bribery and corruption, whatever form it takes.
We are committed to:
- Operating our business in an honest, professional and ethical manner. We do not want to be party to bribery and corruption in any form.
- Complying with anti-bribery and anti-corruption laws worldwide.
- Ensuring that proportionate due diligence is conducted on all business relationships, including agents who act on our behalf.
- Ensuring that no person who works for us suffers any detrimental treatment for raising any genuine concern of bribery or corruption in relation to our business.
In line with our:
- Quality Policy.
- Code of Conduct.
- Anti-bribery and compliance Policy & procedures
- We operate procedures across our businesses and functions to deter, detect and report bribery and corruption in accordance with:
– The US Foreign Corrupt Practices Act (FCPA)
– The UK Bribery Act 2010 and Guidance issued by the Ministry of Justice
– All additional applicable legislation as this applies (e.g. OECD Convention, etc.). - Every entity and function at Neopharm must:
– Regularly review all risk factors relevant to the business’s activities, third party relationships in place to ensure adequate bribery and corruption measures remain in place.
– Ensure all payments are made or accepted in accordance with contractual obligations. - We provide anti-bribery and anti-corruption training and guidance to our partners and employees.
- Every entity and function adhere to this policy and associated guidance, including escalating and assisting with the investigation of any reported bribery and corruption concerns.
- We take policy non-compliance very seriously. Exceptions are reported and managed through our mechanisms, including disciplinary actions.
